Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 5

PIK3CA and TP53 MUTATIONS andSALL4, PTEN and PIK3R1 GENE EXPRESSIONLEVELS in BREAST CANCER

MEME KANSERİNDE PIK3CA ve TP53 MUTASYONLARI ve SALL4, PTEN ve PIK3R1 GEN EKSPRESYON SEVİYELERİ

Pages
515–523
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PIK3R1 and PTEN expression levels showed statistically significant, respectively in G3 grades, ER(+), (PR)(+), HER2(+) and ER(+).Conclusions: We suggest that these candidate genes could be potential prognostic biomarkers of BCa and that they should be considered in the evaluation of clinical parameters of BCa.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: A high frequency of PI3K signalling pathway abnormalities and TP53 mutations are critical in the development and progression of breast cancer (BCa).
📊
Key Findings & Data:We aimed to detect PIK3CA and TP53 mutations via an expression analysis of PIK3R1, PTEN and SALL4 and correlate the expression of these genes with clinical parameters of BCa.Materials and methods: PIK3CA and TP53 mutations in BCa samples were analysed by High-Resolution Melting (HRM) analysis, followed by Sanger sequencing, and the expression levels of PIK3R1, PTEN and SALL4 were evaluated by RT-PCR methods.Results: The frequency of PIK3CA and TP53 mutations was 42% and 38% according to the HRM and Sanger sequencing.
💡
Conclusion & Impact:PIK3R1 and PTEN expression levels showed statistically significant, respectively in G3 grades, ER(+), (PR)(+), HER2(+) and ER(+).Conclusions: We suggest that these candidate genes could be potential prognostic biomarkers of BCa and that they should be considered in the evaluation of clinical parameters of BCa.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: A high frequency of PI3K signalling pathway abnormalities and TP53 mutations are critical in the development and progression of breast cancer (BCa). We aimed to detect PIK3CA and TP53 mutations via an expression analysis of PIK3R1, PTEN and SALL4 and correlate the expression of these genes with clinical parameters of BCa.Materials and methods: PIK3CA and TP53 mutations in BCa samples were analysed by High-Resolution Melting (HRM) analysis, followed by Sanger sequencing, and the expression levels of PIK3R1, PTEN and SALL4 were evaluated by RT-PCR methods.Results: The frequency of PIK3CA and TP53 mutations was 42% and 38% according to the HRM and Sanger sequencing. There was a significantly high frequency of these mutations in ER(+), N0 and HER2(−) tumour samples. PIK3R1 and PTEN expression levels were high in tumour samples, whereas SALL4 expression was low. In patients with TP53 mutations, PIK3R1 expression was low, and this finding was statistically significant. PIK3R1 and PTEN expression levels showed statistically significant, respectively in G3 grades, ER(+), (PR)(+), HER2(+) and ER(+).Conclusions: We suggest that these candidate genes could be potential prognostic biomarkers of BCa and that they should be considered in the evaluation of clinical parameters of BCa.

Özet

Amaç: Yüksek frekanstaki PI3K sinyal yolağı anormal likleri ve TP53 mutasyonları, meme kanseri gelişimi veilerlemesinde kritik öneme sahiptir. Bu çalışmanın amacıPIK3CA ve TP53 mutasyonları ile PIK3R1, PTEN ve SALL4ekspresyon analizi ve bunların meme kanser klinik para metreleri ile ilişkisini belirlemektir. Gereç ve Yöntem: Meme kanser örneklerinde Yüksek Çözü nürlüklü Erime (HRM) analizi ile PIK3CA ve TP53 mutas yonları analiz, Sanger dizi takibi ve PIK3R1, PTEN ve SALL4ekspresyon seviyeleri RT-PZR yöntemiyle değerlendirildi. Sonuçlar: HRM analizi ve dizilemeyle, PIK3CA veTP53 mutasyon frekansı %42 ve %38 olarak bulundu. Bumutasyonlar sırasıyla ER(+), N0 ve HER2(−) tümör örnek lerinde yüksek ve istatiksel olarak anlamlı görülmüştür.SALL4 ekspresyonu tümör örneklerinde düşük olmasınakarşın, PIK3R1 ve PTEN ekspresyon seviyeleri yüksekti.TP53 mutasyonu taşıyan hastalarda PIK3R1 ekspresyonudüşük ve istatiksel olarak anlamlı bulundu. PIK3R1 vePTEN ekspresyon seviyeleri sırasıyla G3 dereceli, ÖR(+),PR(+), HER2(+) ve ÖR(+)’lerde istatiksel olarak anlamlıolduğu gösterildi. Sonuç: Biz bu aday genlerin meme kanserinde prognoz tik biyo-belirteç olma potansiyellerinin olabileceğini veböylece bunların meme kanserinde klinik parametrele rin değerlendirilmesinde dikkat edilmesi gerektiğini ilerisürüyoruz.

🔖

Cite This Article

KAYA, H., GÜLLÜOĞLU, B. M., UĞURLU, M. Ü., AKKİPRİK, M., SEVEN, İ. E., ÖZER, A., DİRİCAN, E., PEKER, İ. (2022). PIK3CA and TP53 MUTATIONS andSALL4, PTEN and PIK3R1 GENE EXPRESSIONLEVELS in BREAST CANCER. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 5, 515–523. https://ajindex.com/articles/620804

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast Cancer 2014;6:1–13
  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86
  3. Naushad SM, Divya C, JanakiRamaiah M, Hussain T, Alrokayan SA, Kutala VK. Population-level diversity in the association of genetic polymorphisms of one-carbon metabolism with breast cancer risk. J Community Genet 2016;7:279–90
  4. Cancer Genome Atlas N. Comprehensive molecular por traits of human breast tumours. Nature 2012;490:61–70
  5. Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/ mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat 2018;169:397–406
  6. LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol 2016;34:3803–15
  7. Catalogue of Somatic Mutations in Cancer (COSMIC). Date of Access: 15 May 2018.
  8. Hesari A, Rajab S, Rezaei M, Basam M, Golmohamadi S, Ghasemi F. Knockdown of Sal-like 4 expression by siRNA induces apoptosis in colorectal cancer. J Cell Biochem 2019;120:11531–8
  9. Dirican E, Kaya Z, Gullu G, Peker I, Ozmen T, Gulluoglu BM, et al. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer. Asian Pac J Cancer Prev 2014;15:9327–33
  10. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Panel members- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206–23
  11. Ney JT, Froehner S, Roesler A, Buettner R, Merkelbach-Bruse S. High- resolution melting analysis asa sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. Arch Pathol Lab Med 2012;136:983–92
  12. Yamanoshita O, Kubota T, Hou J, Ping YM, Zhang XL, Li XP, et al. DHPLC is superior to SSCP in screeningp53mutations in esophageal cancer tissues. Int J Cancer 2005;114:74–9
  13. Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, et al. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer Sci 2018;109:2558–66
  14. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, I